Orbis BioCapital Limited reported 499,926 Class A ordinary shares, equal to 9.98% of Universe Pharmaceuticals INC. The passive designation matters because the certification says the securities were not acquired or held to change or influence control, except for nomination-related activities.

Key Highlights

  • Orbis BioCapital Limited used a Schedule 13G under Rule 13d-1(c) to report the position.
  • Chunhua Zheng is identified as Orbis BioCapital Limited’s sole owner and controller.
  • Orbis BioCapital Limited and Chunhua Zheng agreed to a joint filing signed September 1, 2026.

Universe Pharmaceuticals INC (NASDAQ: UPC) is the subject of a 9.98% ownership report from Orbis BioCapital Limited. The position covers 499,926 Class A ordinary shares.

Orbis BioCapital Limited submitted the position through a Schedule 13G under Rule 13d-1(c), with the securities identified as Class A ordinary shares. Orbis is a limited-liability company formed in the British Virgin Islands. The reported holding is attributed to both Orbis and Zheng at 499,926 shares and 9.98%. Universe Pharmaceuticals is described as a Cayman Islands exempted company, while Zheng’s listed domicile is the People’s Republic of China.

Ownership Certification Addresses Control Purpose

The ownership certification states that the securities were not acquired or held to change or influence control of Universe Pharmaceuticals. It also says they were not acquired or held in connection with a transaction having that purpose or effect. The certification preserves an exception for activities solely connected with a nomination under Section 240.14a-11. Orbis and Zheng agreed to submit the ownership statement jointly under Rule 13d-1(k), with Zheng signing as Orbis’ director on September 1, 2026.